Fat loss is one of the most discussed — and most misunderstood — applications in the peptide space. The GLP-1 revolution (semaglutide, tirzepatide) has brought peptide-based metabolic intervention into mainstream awareness, but the landscape extends well beyond GLP-1 agonists. A range of research peptides targets fat metabolism through distinct mechanisms: reducing appetite, enhancing fat oxidation, improving insulin sensitivity, stimulating growth hormone (which promotes lipolysis), and directly targeting adipose tissue.
This article covers the peptides most commonly used for fat loss and metabolic health — their specific mechanisms, how they’re typically used, and what the evidence and user experience suggest.
A Note on Fat Loss Mechanisms
Sustainable fat loss requires a caloric deficit — no peptide changes that fundamental equation. What certain peptides can do is make that deficit easier to maintain (by reducing appetite), improve the composition of what you’re losing (preserving or building lean mass while accelerating fat oxidation), or address specific metabolic dysfunction that makes fat loss disproportionately difficult.
Understanding which mechanism is most relevant to your situation helps determine which peptides are most appropriate.
The Stack
AOD-9604
What it is: AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone — specifically the C-terminal end (amino acids 176–191) that contains the fat-regulating properties of HGH without its anabolic or insulin-sensitizing effects. It was originally developed by Monash University in Australia specifically for obesity treatment.
How it works:
- Mimics the way natural growth hormone stimulates fat breakdown (lipolysis) in adipose tissue
- Inhibits lipogenesis — the process by which the body converts carbohydrates and other substrates into stored fat
- Does not raise IGF-1 levels or have anabolic effects, which distinguishes it from full-sequence growth hormone or secretagogues
- Has demonstrated a favorable safety profile in Phase 2 and Phase 3 clinical trials (it progressed further in clinical development than most research peptides discussed in this series)
What users report: Noticeable changes in body fat, particularly around the abdomen, over 8–12 week cycles. Often described as “targeted” fat reduction, though the mechanisms are systemic rather than spot-reducing. Most effective when combined with appropriate nutrition and training.
Typical dosing: 300–600 mcg subcutaneously once daily, typically taken in the morning before food or exercise.
Approximate pricing: $50–$90 per 6mg vial. Monthly cost approximately $80–$150.
Pricing shown reflects research vendor market rates as of publication. Physician-compounded versions through licensed pharmacies are priced differently and include clinical oversight, quality testing, and prescription fulfillment.
Tesamorelin
What it is: Tesamorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) with a particularly strong evidence base for visceral fat reduction. It is FDA-approved under the brand name Egrifta for the treatment of HIV-associated lipodystrophy (excess visceral fat accumulation), making it one of the few peptides in this series with genuine regulatory approval.
Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy. Its use for general body composition goals is off-label. Off-label use of prescription medications should only occur under physician supervision and with informed consent.
How it works:
- Stimulates the pituitary gland to release growth hormone, which in turn promotes lipolysis (fat breakdown) throughout the body
- Has demonstrated particularly pronounced effects on visceral adipose tissue — the metabolically dangerous fat stored around internal organs
- Improves lipid profiles (triglycerides, HDL) in research subjects alongside its body composition effects
- Preserves or builds lean mass simultaneously, making it relevant to body recomposition goals
What users report: Significant reductions in belly fat over 12–24 week protocols. Body recomposition results — losing fat while maintaining or gaining muscle — are among the most consistent reports. Sleep quality improvements are also common, consistent with elevated GH output.
Typical dosing: 1–2mg subcutaneously once daily in the morning.
Approximate pricing: $100–$180 per 2mg vial. Given daily dosing, monthly cost is approximately $200–$400.
5-Amino-1MQ
What it is: 5-Amino-1MQ is a small molecule compound (technically not a peptide, but frequently included in metabolic stacks) that inhibits an enzyme called NNMT (Nicotinamide N-methyltransferase). NNMT is found in fat tissue and plays a role in regulating fat cell metabolism and energy storage. In obesity, NNMT activity is elevated, contributing to metabolic slowdown and increased fat storage.
How it works:
- Inhibiting NNMT raises NAD+ levels inside fat cells, which activates SIRT1 — a key longevity and metabolic enzyme
- This shifts fat cells toward a metabolically active, fat-burning state rather than a fat-storing state
- Animal studies have shown significant reductions in fat mass without caloric restriction when NNMT is inhibited
- May support the creation of new, metabolically healthy fat cells (beige adipocytes) that burn energy rather than store it
What users report: Still an emerging compound with limited widespread user data. Reports describe improved energy and body composition changes, particularly when combined with caloric management. Considered a promising metabolic support compound rather than a primary fat-loss agent.
Typical dosing: 50–100mg orally per day.
Approximate pricing: $60–$100 per 30-day supply.
Note: 5-Amino-1MQ is not among the compounds expected to return to physician-supervised compounding pharmacy access under current regulatory discussions. Its regulatory and safety status should be verified before researching further.
MOTS-c
What it is: MOTS-c was introduced in the Energy & Performance stack for its role in cellular energy production. In the metabolic context, it earns a second appearance because of its potent effects on insulin sensitivity, glucose metabolism, and exercise-induced fat oxidation.
Metabolic mechanisms:
- Activates AMPK, improving cellular glucose uptake and fatty acid oxidation — the metabolic pathway by which fat is converted to energy
- Improves insulin sensitivity in muscle tissue, reducing the metabolic disruption caused by insulin resistance
- Exercise performance improvements from MOTS-c result in more total work capacity, which supports a greater caloric expenditure
- In aged and obese animal models, MOTS-c administration has reversed diet-induced metabolic dysfunction
For anyone dealing with insulin resistance, metabolic syndrome, or difficulty losing fat despite appropriate effort, MOTS-c addresses a root biological cause rather than just symptoms.
Typical dosing: 5–10 mg subcutaneously, 2–3x per week.
Approximate pricing: $65–$100 per 10mg vial. See the Energy Stack for more detail.
Tesamorelin vs. CJC-1295 + Ipamorelin for Fat Loss
A common question is whether Tesamorelin (a direct GHRH analog) or the CJC-1295 + Ipamorelin combination from the muscle building stack is the better choice for fat loss. The short answer:
- Tesamorelin has the strongest specific evidence for visceral fat reduction and is the more targeted choice if body fat is the primary goal
- CJC-1295 + Ipamorelin is more versatile, supporting both muscle building and fat loss simultaneously, and may be the better choice for recomposition-focused users
Many users with dual goals (muscle preservation + fat loss) combine AOD-9604 with CJC-1295 + Ipamorelin rather than using Tesamorelin, to get targeted lipolysis alongside GH secretagogue benefits.
Putting the Stack Together
Core fat loss stack:
- AOD-9604: 300–500 mcg subcutaneous, morning (fasted if possible)
- Tesamorelin: 1mg subcutaneous, daily (most targeted for visceral fat)
Recomposition-focused stack:
- CJC-1295 (no DAC) + Ipamorelin: nightly
- AOD-9604: morning
- MOTS-c: 3x per week
Metabolic health / insulin resistance focus:
- MOTS-c: 3x per week
- 5-Amino-1MQ: daily oral
- AOD-9604: daily
Estimated monthly cost:
- AOD-9604 + Tesamorelin core: $300–$550/month
- Full recomposition stack: $350–$600/month
Timeline Expectations
AOD-9604 effects on body composition typically become noticeable at 6–8 weeks. Tesamorelin produces measurable changes in visceral fat area at 12–24 weeks in clinical trials. MOTS-c metabolic improvements — particularly insulin sensitivity — are reported within 4–6 weeks of regular use.
These compounds work best alongside a caloric strategy appropriate to your goals. They are not a substitute for dietary discipline but can meaningfully improve results and support long-term adherence.
Related Stacks
- Muscle Building & Body Composition — CJC-1295, Ipamorelin, and MK-677 for the anabolic/recomposition side of the equation
- Energy, Focus & Performance — MOTS-c in more detail
- Hormonal Support & Longevity — growth hormone optimization from a longevity perspective
Health Disclaimer
BodyCircuit’s content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed physician before beginning any peptide or wellness protocol. The regulatory status of peptides discussed in this series is evolving — some compounds are FDA-approved, some are expected to return to legal compounding status through physician prescription, and others remain restricted to research use only. BodyCircuit will update this series as regulatory guidance changes. Nothing in this series constitutes an endorsement, recommendation, or offer to sell any compound.
BodyCircuit